Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2024-09-09 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
2024年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the company's 2024 fourth extraordinary general meeting of shareholders, including voting results, attendance, and legal witness statements. It does not contain financial statements or performance data but focuses on shareholder meeting outcomes and board-related decisions. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2042 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2024-09-09 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The length is 2305 characters, which is relatively short, but it contains substantive financial data and analysis for the half-year period, not just an announcement or a link. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis. It is not a mere announcement or certification, so it is not RPA or RNS. Hence, the correct classification is IR with high confidence. H1 2024
2024-08-30 Chinese
2024年第二季度主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (701 characters) presenting the company's main operating data for the second quarter of 2024. It includes contract signing details and sales volume data but does not contain full financial statements or detailed financial analysis. The document is titled as a '主要经营数据公告' (main operating data announcement) and is issued by the company's board. It is not a full interim or quarterly report (IR) because it lacks comprehensive financial statements and substantive financial data. It is also not an earnings release (ER) since it provides operational data rather than key financial highlights. Given the short length and nature of the content, this fits best as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and disclosures that do not fit other categories.
2024-08-30 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It covers the period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, assets, liabilities, and management discussion and analysis. It also contains sections on company overview, business segments, risk disclosures, and forward-looking statements. The length of the document (15,000 characters) and the presence of substantive financial statements and analysis confirm it is a comprehensive interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-30 Chinese
关于公司2024年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) activities, specifically focusing on the storage and actual use of funds raised in 2024 half-year period. It includes detailed financial figures about the amount raised, usage in previous years, current usage, balance, management policies, and compliance with regulatory requirements. The document references approvals from the China Securities Regulatory Commission and includes audit verification reports related to the fundraising. The content is focused on the use and management of capital raised through a non-public stock issuance, with no indication of it being a general financial report, earnings release, or management discussion. It is not a brief announcement but a comprehensive report on capital usage. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (7624 characters) and detailed financial data support it being a substantive report rather than a mere announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-08-30 Chinese
第四届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Tianyu Bio-Tech Co., Ltd. It details the convening and decisions of the 31st meeting of the 4th board of directors, including approval of the 2024 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and special report as being published elsewhere (Shanghai Stock Exchange website), indicating this document itself is not the full semi-annual report but an announcement of board resolutions related to those reports. The document is short (830 characters) and serves as a formal announcement of board decisions rather than containing substantive financial data or the full report. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and approvals.
2024-08-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.